前往主要內容區間
掛號頁面

細胞與再生醫療中心

細胞與再生醫療中心
  • 張義芳醫師相片

    張義芳

    主治醫師

    血液暨腫瘤科 :
    台北門診掛號  
    專科諮詢門診 :
    台北門診掛號  
    信望愛特別門診 :
    台北門診掛號  

    張義芳醫師本頁二維碼

  • 現職

      台東馬偕紀念醫院 副院長
      馬偕紀念醫院 血液腫瘤科 資深主治醫師

    主要學歷

      臺北醫學大學 臨床醫學研究所博士
      臺北醫學大學 醫學研究所碩士
      中國醫藥大學 醫學士

    主要經歷

      馬偕紀念醫院 院長室專員
      馬偕紀念醫院 癌症委員會主席
      馬偕紀念醫院 臨床試驗中心主任
      馬偕紀念醫院 癌症中心主任
      馬偕紀念醫院 細胞暨再生醫療中心主任
      馬偕紀念醫院 血液腫瘤科主任
      馬偕紀念醫院 血液腫瘤科 資深主治醫師
      馬偕醫學院醫學系 助理教授
      台灣免疫腫瘤醫學會 監事暨出版主委
      癌症安寧緩和醫學會 秘書長、理監事
      臺灣頭頸癌醫學會 理事 、監事
      臺灣癌症資訊全人關懷協會 理事

    其他相關

      <學會會員>
      台灣內科醫學會
      中華民國癌症醫學會
      中華民國血液病學會
      台灣安寧緩和醫學會
      台灣頭頸部腫瘤醫學會
      <證書>
      醫師證書
      內科專科醫師證書
      中華民國血液病專科醫師證書
      中華民國腫瘤內科專科醫師證書

主治項目或專長

各類惡性腫瘤、轉移性癌症、血液病、淋巴癌、免疫治療、細胞治療、精準治療, 同時多癌治療諮詢。


論文研究

  1. Chang PS, Chen YC, Hua WK, Hsu JC, Tsai JC, Huang YW, Kao YH, Wu PH, Wang PN, Chang YF*, Chang MC, Chang YC, Jian SL, Lai JS, Lai MT, Yang WC, Shen CN, Wen KK, Wu SC. Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-TSCM cells using a Quantum pBac-based CAR-T engineering system. PLoS One. 2024 Aug 27;19(8):e0309245.

  2. Chang YC, Chiang YH, Hsu K, Chuang CK, Kao CW,Chang YF*, Chang MC, Lim KH, Cheng HI, Hsu YN, Chen CG. Activated naïve γδ T cells accelerate deep molecular response to BCR-ABL inhibitors in patients with chronic myeloid leukemia. Blood Cancer Journal 2021 Nov 16; 11(11): 182.

  3. Wang CI, Chang YF*(共同), Sie ZL, Ho AS, Chang JS, Peng CL, Cheng CC. Irradiation suppresses IFNγ-mediated PD-L1 and MCL1 expression in EGFR-positive lung cancer to augment CD8+ T cells cytotoxicity. Cells 2021 Sep 23; 10(10):2515. 

  4. Cheng CC, Chang YF*, Ho AS, Sie ZL, Chang CL, Chang CC. Irradiation mediates IFNα and CXCL9 expression in non-small cell lung cancer to stimulate CD8+ T cells activity and migration toward tumors. Biomedicines 2021 Sep 29; 9(10):1349. 

  5. Su CW, Lee JC, Chang YF*, Su NW, Lee PH, Dai KY, Tai HC, Leu YS, Chen YJ. Delta-volume radiomics of induction chemotherapy to predict outcome of subsequent chemoradiotherapy for locaaly advanced hypopharyngeal cancer. Tumori. 2021 Aug 21.

  6. Lim KH, Wu JN, Huang TY, Jhuang JY, Chang YC, Lin HC, Chiang YH, Su YW, Chen GS, Chang YF*, Lim J. Clonal evolution and heterogeneity in advanced systemic mastocytosis revealed by single-cell DNA sequencing. Blood Adv. 2021 Mar 23; 5(6): 1733-36 

  7. Cheng CC, Lin HC, Chiang YW, Chang J, Sie ZL, Yang BL, Lim KH, Peng CL, Ho AS,Chang YF*. Nicotine exhausts CD8+ T cells against tumor cells through increasing miR-629-5p to repress IL2RB-mediated granzyme B expression. Cancer Immunol Immunother. 2021 May 70(5): 1351-64.

  8. Lim KM, Chen LC, Hsu K, Chang CC, Chang CY, Kao CW, Chang YF*, Chang MC, Chen CG. BAFF-driven NLRP3 inflammasome activation in B cells. Cell Death & Disease 2020 Oct 1; 11(9): 820.

  9. Chang YF*, Lim KH, Chiang YW, Sie ZL, Ho AS, Cheng CC. STAT3 induces G9a to exacerbate HER3 expression for the survival of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancer. BMC Cancer. 2019 Oct 16; 19(1):959.

  10. Chang MC, Cheng HI, Hsu K, Hsu YN, Kao CW, Chang YF*, Lim KH, Chen CG. NKG2A down-regulation by Dasatinib enhances natural killer cytotoxicity and accelerates effective treatment responses in patients with chronic myeloid leukemia. Front Immunol. 2019 Jan 17; 9:3152.

  11. Cheng CC, Lin HC, Tsai KJ, Chiang YW, Lim KH, Chen CG, Su YW, Peng CL, Ho AS, Huang L, Chang YC, Lin HC, Chang J, Chang YF*. Epidermal growth factor induces STAT1 expression to exacerbate the IFNr-mediated PD-L1 axis in epidermal growth factor receptor-positive cancers. Mol Carcinog. 2018 Nov; 57(11):1588-98.

  12. Cheng CC, Liao PN, Ho AS, Lim KH, Chang J, Su YW, Chen CG, Chiang YW, Yang BL, Lin HC, Chang YC, Chang CC, Chang YF*. STAT3 exacerbates survival of cancer stem-like tumorspheres in EGFR-positive colorectal cancers: RNAseq analysis and therapeutic screening. J Biomed Sci. 2018 Aug 2; 25(1):60.

  13. Chen MJ, Wu IC, Chen YJ, Wang TE, Chang YF*, Yang CL, Huang WC, Chang WK, Sheu BS, Wu MS, Lin JT, Chu CH. Nutrition therapy in esophageal cancer-consensus statement of the gastroenterological society of Taiwan. Dis Esophagus. 2018 Aug 1; 31(8).

  14. Cheng CC, Chou KF, Wu CW, Su NW, Peng CL, Su YW, Chang J, Ho AS, Lin HC, Chen CG, Yang BL, Chang YC, Chiang YW, Lim KH, Chang YF*. EGFR-mediated interleukin enhancer-binding factor 3 contributes to formation and survival of cancer stem-like tumorspheres as a therapeutic target against EGFR-positive non-small cell lung cancer. Lung Cancer. 2018 Feb; 116: 80-89.

  15. Shih BB, Chang YF*, Cheng CC, Yang HJ, Chang KW, Ho AS, Lin HC, Yeh C, Chang CC. SPECT imaging evaluation of 111indium-chelated cetuximab for diagnosing EGFR-positive tumor in an HCT-15-induced colorectal xenograft. J Chin Med Assoc. 2017 Dec; 80(12):766-73.

  16. Chiang YH, Chang YC, Lin HC, Huang L, Cheng CC, Wang WT, Cheng HI, Su NW, Chen CG, Lin J, Chang YF*, Chang MC, Hsieh RK, Chou WC, Lim KH, Kuo YY. Germline variations at JAK2, TERT, HBS1L-MYB and MECOM and the risk of myeloproliferative neoplasms in Taiwanese population. Oncotarget. 2017 Jul; 8(44): 76204-13.

  17. Lim KH, Chen GS, Chang YC, Chiang YH, Kao CW, Wang WT, Chang CY, Huang L, Lin CS, Cheng CC, Cheng HI, Su NW, Lin J, Chang YF*, Chang MC, Hsieh RK, Lin HC, Kuo YY. Increased B cell activation is present in JAK2V617F-mutated, CALR-mutated and triple-negative essential thrombocythemia. Oncotarget. 2017 May 16;8(20):32476-32491.

  18. Cheng CC, Chang J, Huang SC, Lin HC, Ho AS, Lim KH, Chang CC, Huang L, Chang YF*, Wu CW. YM155 as an inhibitor of cancer stemness simultaneously inhibits autophosphorylation of epidermal growth factor receptor and G9a-mediated stemness in lung cancer cells. PLoS One. 2017 Aug; 12(8):e0182149.

  19. Chi-Long Chen, Chun-Yi Chiang, Kuang-Wen Liao, Shu-Yi Ho, Yi-Fang Chang*, Ken-Hong Lim, Ruey-Kuen Hsieh, Yu-Ling Lin, Ying-Wen Su. cIAP-2 Expression Increases in Elderly Patients with Squamous Cell Carcinoma of the Head and Neck. International Journal of Gerontology. 2017; 11(1): 22-26.

  20. Yu-Cheng Chang, Huan-Chau Lin, Yi-Hao Chiang, Caleb Gon-Shen Chen, Ling Huang, Wei-Ting Wang, Chun-Chia Cheng, Johnson Lin, Yi-Fang Chang*, Ming-Chih Chang, Ruey-Kuen Hsieh, Shu-Jen Chen, Ken-Hong Lim, Yuan-Yeh Kuo. Targeted next-generation sequencing identified novel mutations in triple-negative myeloproliferative neoplasms. Med Oncol. 2017; 34: 83.

  21. Chang YF*, Hsu YF, Chiu PT, Huang WJ, Huang SW, Ou G, Sheu JR, Hsu MJ. WMJ-S-001, a novel aliphatic hydroxamate derivative, exhibits anti-angiogenic activities via Src-homology-2-domain-containing protein tyrosine phosphatase. Oncotarget. 2015 Jan 1;6(1):85-100.

  22. Su NW, Liu CJ, Leu YS, Lee JC, Chen YJ, Chang YF*.Prolonged radiation time and low nadir hemoglobin during postoperative concurrent chemoradiotherapy are both poor prognostic factors with synergistic effect on locally advanced head and neck cancer patients. Onco Targets Ther. 2015 Jan 28;8:251-8.

  23. Liu SH, Chao KS, Leu YS, Lee JC, Liu CJ, Huang YC, Chang YF*, Chen HW, Tsai JT, Chen YJ.Guideline and preliminary clinical practice results for dose specification and target delineation for postoperative radiotherapy for oral cavity cancer. Head Neck. 2015 Jul;37(7):933-9.

  24. Tsai HJ, Lin SF, Chen CC, Chen TY, Su WC, Hwang WL, Lin JC, Chiou TJ, Kao WY, Chiu CF, Chang YF*, Chang JS, Chang MC, Su IJ. Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma. Eur J Haematol. 2015 Feb;94(2):130-7.

  25. Lim KH, Chang YC, Gon-Shen Chen C, Lin HC, Wang WT, Chiang YH, Cheng HI, Su NW, Lin J, Chang YF*, Chang MC, Hsieh RK, Kuo YY, Chou WC.Frequent CALR exon 9 alterations in JAK2 V617F-mutated essential thrombocythemia detected by high-resolution melting analysis. Blood Cancer J. 2015 Mar 20;5:e295.

  26. Lim KH, Lin HC, Chen CG, Wang WT, Chang YC, Chiang YH, Lin CS, Su NW, Su YW, Lin J, Chang YF*, Chang MC, Hsieh RK, Kuo YY, Chou WC.Rapid and sensitive detection of CALR exon 9 mutations using high-resolution melting analysis. Clin Chim Acta. 2015 Feb 2;440:133-9.

  27. Chien TJ1, Liu CY, Chang YF*, Fang CJ, Hsu CH.Acupuncture for treating aromatase inhibitor-related arthralgia in breast cancer: a systematic review and meta-analysis. J Altern Complement Med. 2015 May;21(5):251-60.

  28. Li YC, Yeh PC, Chen HW, Chang YF*, Pi SH, Fang CK. Posttraumatic growth and demoralization after cancer: The effects of patients' meaning-making. Palliat Support Care. 2015 Mar 5:1-10.

  29. Hsieh JC, Hsu CL, Ng SH, Wang CH, Lee K, Lu CH, Chang YF*, Hsieh RK, Yeh KH, Hsiao CH, Chen SY, Shiau CY, Wang HM.Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: a multicenter prospective Phase II trial. Jpn J Clin Oncol. 2015 Jun 8.

  30. Su NW, Leu YS, Lee JC, Liu CJ, Cheng CY, Lin JS, Chen YJ, Chen CK, Fang IC, Hsieh RK, Chang YF*.EGF and EGFR genetic polymorphisms predict prognosis in locally advanced pharyngolaryngeal squamous cell carcinoma patients receiving postoperative concurrent chemoradiotherapy. Onco Targets Ther. 2014 Nov 28;7:2197-204.

  31. Fang CK, Chang MC, Chen PJ, Lin CC, Chen GS, Lin J, Hsieh RK, Chang YF*, Chen HW, Wu CL, Lin KC, Chiu YJ, Li YC.A correlational study of suicidal ideation with psychological distress, depression, and demoralization in patients with cancer. Support Care Cancer. 2014 Dec;22(12):3165-74.

  32. Su YW, Lin YH, Pai MH, Lo AC, Lee YC, Fang IC, Lin J, Hsieh RK, Chang YF*, Chen CL.Association between phosphorylated AMP-activated protein kinase and acetyl-CoA carboxylase expression and outcome in patients with squamous cell carcinoma of the head and neck. PLoS One. 2014 Apr 25;9(4).

  33. Chang YF*, Lo AC, Tsai CH, Lee PY, Sun S, Chang TH, Chen CC, Chang YS. Higher complication risk of totally implantable venous access port systems in patients with advanced cancer - a single institution retrospective analysis. Chen JR. Palliat Med. 2013 Feb;27(2):185-91